緑内障の世界市場レポート 2025

緑内障市場規模は、今後数年間で力強い成長が見込まれます。2029年の年間平均成長率（CAGR）は5.5％で、102億米ドルに成長します。この予測期間における成長は、高齢化、緑内障の有病率の上昇、低侵襲手術の需要の高まりによって牽引されると予想されます。さらに、緑内障の危険因子である糖尿病や高血圧などの疾患の有病率が上昇していることも、緑内障ケアの需要をさらに高めると思われます。予測期間における主な動向には、診断技術の進歩、新薬治療の利用可能性、手術器具の革新、併用療法の利用可能性、ロボット手術の採用増加などがあり、これらはすべて緑内障管理をより効果的かつ効率的にすることに貢献します。

慢性的な眼疾患の有病率の増加は、緑内障市場の成長を促進すると予想されます。慢性的な眼疾患は、眼に影響を与える長期にわたる疾患で、しばしば継続的な視力障害や不快感を引き起こし、継続的な管理や治療が必要となります。このような症状の増加要因には、人口の高齢化、スクリーン使用時間の増加、ライフスタイルの変化、糖尿病や高血圧などの疾患率の上昇などがあります。治療は眼圧を下げ、視神経のさらなる損傷を防ぎ、視力を維持するのに役立つため、慢性的な目の状態を管理するのに不可欠です。例えば、2024年12月に国民保健サービス（NHS）が発表したところによると、英国では200万人以上の人々が視力低下とともに生活しており、この数は27％増加し、2035年には約280万人に達すると予測されています。その結果、慢性的な眼疾患の有病率が上昇し、緑内障市場の需要を牽引しています。

緑内障市場の主要企業は、二重の作用機序を提供するRho-kinase（ROCK）阻害剤を含む革新的な治療法の開発に注力しています。これらの治療薬は房水の流出を改善し、海綿体網膜細胞を弛緩させることで眼圧を低下させるため、緑内障治療に非常に有効です。Rho-kinase（ROCK）阻害薬は、細胞収縮を制御するRho-kinase酵素を標的として阻害することにより作用し、眼圧を低下させる。例えば、2023年7月、参天製薬株式会社（本社：日本）は、Rho-kinase（ROCK）阻害剤を発表しました。日本を拠点とする参天製薬株式会社は、英国でRoclandaを導入しました。Roclandaは、ラタノプロストと新規のRho-キナーゼ（ROCK）阻害剤であるネタルスジルの合剤（FDC）で、海綿体メッシュワーク機能障害に対処することにより眼圧を低下させるように設計されています。本剤は、プロスタグランジンまたはネタルスジルの単剤療法で十分な眼圧下降が得られない原発性開放隅角症または高眼圧症の成人患者を対象としています。欧州におけるRoclandaの発売は、25年ぶりの新しいクラスの緑内障治療薬であり、治療における大きな進歩を意味します。netarsudilとlatanoprostを組み合わせることにより、Roclandaは海綿体（従来型）とぶどう膜強膜（非従来型）の両方の経路を通じて流出を促進し、眼圧上昇を管理するための包括的なソリューションを提供します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界緑内障PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の緑内障市場：成長率分析
• 世界の緑内障市場の実績：規模と成長, 2019-2024
• 世界の緑内障市場の予測：規模と成長, 2024-2029, 2034F
• 世界緑内障総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の緑内障市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オープンアングル緑内障
• 角度閉鎖緑内障
• その他の病気の種類
• 世界の緑内障市場診断別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 眼圧測定
• 眼底検査
• 視野検査
• 隅角鏡検査
• 世界の緑内障市場薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ベータ遮断薬
• プロスタグランジン
• アルファアドレナリン作動薬
• 炭酸脱水酵素阻害剤
• 併用薬
• その他の薬物クラス
• 世界の緑内障市場管理局による、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射
• 硝子体内
• その他の政権
• 世界の緑内障市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 眼科クリニック
• 外来手術センター
• 世界の緑内障市場開放隅角緑内障の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• プライマリーオープンアングル緑内障（POAG）
• 二次開放角緑内障
• 世界の緑内障市場閉塞隅角緑内障の分類（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 一次隅角閉鎖緑内障
• 二次角閉鎖緑内障
• 世界の緑内障市場、その他の疾患タイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ノーマルテンション緑内障
• 色素性緑内障
• 擬似剥離緑内障
• 先天性緑内障

第7章 地域別・国別分析

• 世界の緑内障市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の緑内障市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 緑内障市場：競合情勢
• 緑内障市場：企業プロファイル
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Otsuka Pharmaceutical Co. Ltd.
• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Bausch & Lomb Corp.
• Carl Zeiss Meditec
• Santen Pharmaceuticals Co. Ltd.
• Topcon Corporation
• Thea Laboratoires
• Corza Ophthalmology
• Lumenis Ltd.
• Alcon Inc.
• Viva Bioイノベーター
• Glaukos Corporation
• Iridex Corporation
• Nova Eye Medical Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 緑内障市場2029：新たな機会を提供する国
• 緑内障市場2029：新たな機会を提供するセグメント
• 緑内障市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Glaucoma refers to a group of eye conditions that damage the optic nerve, typically due to increased intraocular pressure (IOP). If left untreated, this damage can lead to progressive and irreversible vision loss, making glaucoma one of the leading causes of blindness worldwide. Early detection through regular eye exams is essential to prevent vision impairment.

The primary types of glaucoma are open-angle glaucoma, angle-closure glaucoma, and others. Open-angle glaucoma occurs when the eye's drainage angle remains open, but the trabecular meshwork becomes progressively blocked, resulting in elevated IOP. It can be diagnosed using various methods such as tonometry, ophthalmoscopy, perimetry, and gonioscopy. Treatment includes several drug classes, including beta-blockers, prostaglandins, alpha-adrenergic agonists, carbonic anhydrase inhibitors, and combination drugs. These treatments are administered through oral medications, injections, intravitreal injections, and other routes, with end users such as hospitals, ophthalmic clinics, and ambulatory surgical centers.

The glaucoma market research report is one of a series of new reports from The Business Research Company that provides glaucoma market statistics, including glaucoma industry global market size, regional shares, competitors with a glaucoma market share, detailed glaucoma market segments, market trends and opportunities, and any further data you may need to thrive in the glaucoma industry. This glaucoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The glaucoma market size has grown strongly in recent years. It will grow from $7.76 billion in 2024 to $8.22 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to factors such as increasing awareness of eye health, rising healthcare spending, the growing adoption of telemedicine for eye care, expanding healthcare infrastructure, and increased government healthcare initiatives. These factors have contributed to better detection, treatment, and management of glaucoma, helping more individuals access the care they need.

The glaucoma market size is expected to see strong growth in the next few years. It will grow to $10.20 billion in 2029 at a compound annual growth rate (CAGR) of 5.5%. The growth in the forecast period is expected to be driven by the aging population, rising prevalence of glaucoma, and the growing demand for minimally invasive surgeries. Additionally, the rising prevalence of conditions such as diabetes and hypertension, which are risk factors for glaucoma, will further fuel demand for glaucoma care. Major trends in the forecast period include advancements in diagnostic technologies, the availability of new drug treatments, innovations in surgical devices, the availability of combination therapies, and the increasing adoption of robotic surgeries, all of which will contribute to more effective and efficient glaucoma management.

The increasing prevalence of chronic eye conditions is expected to drive growth in the glaucoma market. Chronic eye conditions are long-lasting disorders that impact the eyes, often causing ongoing vision impairment or discomfort, necessitating continuous management or treatment. Factors contributing to the rise of these conditions include an aging population, more screen time, lifestyle changes, and higher rates of diseases such as diabetes and hypertension. Glaucoma treatment is essential for managing chronic eye conditions, as it helps lower intraocular pressure, prevents further damage to the optic nerve, and preserves vision, with untreated glaucoma potentially leading to irreversible blindness. For example, in December 2024, the National Health Service (NHS) reported that over 2 million people in the UK are living with sight loss, a number projected to grow by 27%, reaching approximately 2.8 million by 2035. As a result, the rising prevalence of chronic eye conditions is driving demand in the glaucoma market.

Leading companies in the glaucoma market are focusing on the development of innovative treatments, including Rho-kinase (ROCK) inhibitors, which provide a dual mechanism of action. These therapies reduce intraocular pressure by improving the outflow of aqueous humor and relaxing trabecular meshwork cells, making them highly effective in glaucoma treatment. Rho-kinase (ROCK) inhibitors work by targeting and blocking the Rho-kinase enzymes, which regulate cell contraction and help decrease intraocular pressure. For example, in July 2023, Santen Pharmaceutical Co. Ltd., based in Japan, introduced Roclanda in the UK. Roclanda is a fixed-dose combination (FDC) of latanoprost and netarsudil, a novel Rho-kinase (ROCK) inhibitor, designed to lower intraocular pressure (IOP) by addressing trabecular meshwork dysfunction. It is intended for adult patients with primary open-angle glaucoma or ocular hypertension who have not achieved sufficient IOP reduction with monotherapy involving prostaglandin or netarsudil. The launch of Roclanda in Europe marks the first new class of glaucoma medication in 25 years, representing a significant advancement in treatment. By combining netarsudil and latanoprost, Roclanda enhances outflow through both trabecular (conventional) and uveoscleral (unconventional) pathways, offering a comprehensive solution for managing elevated IOP.

In December 2024, Bausch + Lomb Corp., a Canada-based healthcare company, acquired Elios Vision Inc., a U.S.-based developer of minimally invasive glaucoma surgery (MIGS) procedures. The acquisition is expected to enhance Bausch + Lomb's glaucoma treatment options by providing solutions that do not require implants. This move reflects the company's commitment to advancing technologies that support eye care professionals in addressing patients' evolving needs.

Major players in the glaucoma market are Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Novartis AG, Teva Pharmaceuticals Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Sun Pharmaceutical Industries Ltd., Cipla Limited, Bausch & Lomb Corp., Carl Zeiss Meditec, Santen Pharmaceuticals Co. Ltd., Topcon Corporation, Thea Laboratoires, Corza Ophthalmology, Lumenis Ltd., Alcon Inc., Viva BioInnovator, Glaukos Corporation, Iridex Corporation, Nova Eye Medical Ltd., Renova Life Sciences Private Limited, Qlaris Bio Inc., PolyActiva Pty Ltd., Nidek Co. Ltd., Haag-Streit AG.

North America was the largest region in the glaucoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in glaucoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the glaucoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The glaucoma market consists of revenues earned by entities by providing services such as surgical services, telemedicine consultations, treatment monitoring and custom surgical planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The glaucoma market also includes sales of laser treatment devices, glaucoma drainage implants, visual field analyzers and surgical tools. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Glaucoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on glaucoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for glaucoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The glaucoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Disease Type: Open Angle Glaucoma; Angle Closure Glaucoma; Other Disease Types
• 2) By Diagnosis: Tonometry; Ophthalmoscopy; Perimetry; Gonioscopy
• 3) By Drug Class: Beta Blockers; Prostaglandins; Alpha Adrenergic Agonist; Carbonic Anhydrase Inhibitors; Combination Drugs; Other Drug Classes
• 4) By Administration: Oral; Injections; Intravitreal; Other Administrations
• 5) By End-User: Hospitals; Ophthalmic Clinics; Ambulatory Surgical Centers
• Subsegments:
• 1) By Open Angle Glaucoma: Primary Open Angle Glaucoma (POAG); Secondary Open Angle Glaucoma
• 2) By Angle Closure Glaucoma: Primary Angle Closure Glaucoma; Secondary Angle Closure Glaucoma
• 3) By Other Disease Types: Normal-Tension Glaucoma; Pigmentary Glaucoma; Pseudoexfoliative Glaucoma; Congenital Glaucoma
• Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; AbbVie Inc.; Novartis AG; Teva Pharmaceuticals Industries Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Glaucoma Market Characteristics

3. Glaucoma Market Trends And Strategies

4. Glaucoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Glaucoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Glaucoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Glaucoma Market Growth Rate Analysis
• 5.4. Global Glaucoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Glaucoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Glaucoma Total Addressable Market (TAM)

6. Glaucoma Market Segmentation

• 6.1. Global Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Open Angle Glaucoma
• Angle Closure Glaucoma
• Other Disease Types
• 6.2. Global Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Tonometry
• Ophthalmoscopy
• Perimetry
• Gonioscopy
• 6.3. Global Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Beta Blockers
• Prostaglandins
• Alpha Adrenergic Agonist
• Carbonic Anhydrase Inhibitors
• Combination Drugs
• Other Drug Classes
• 6.4. Global Glaucoma Market, Segmentation By Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injections
• Intravitreal
• Other Administrations
• 6.5. Global Glaucoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Ophthalmic Clinics
• Ambulatory Surgical Centers
• 6.6. Global Glaucoma Market, Sub-Segmentation Of Open Angle Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Open Angle Glaucoma (POAG)
• Secondary Open Angle Glaucoma
• 6.7. Global Glaucoma Market, Sub-Segmentation Of Angle Closure Glaucoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Primary Angle Closure Glaucoma
• Secondary Angle Closure Glaucoma
• 6.8. Global Glaucoma Market, Sub-Segmentation Of Other Disease Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Normal-Tension Glaucoma
• Pigmentary Glaucoma
• Pseudoexfoliative Glaucoma
• Congenital Glaucoma

7. Glaucoma Market Regional And Country Analysis

• 7.1. Global Glaucoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Glaucoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Glaucoma Market

• 8.1. Asia-Pacific Glaucoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Glaucoma Market

• 9.1. China Glaucoma Market Overview
• 9.2. China Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Glaucoma Market

• 10.1. India Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Glaucoma Market

• 11.1. Japan Glaucoma Market Overview
• 11.2. Japan Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Glaucoma Market

• 12.1. Australia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Glaucoma Market

• 13.1. Indonesia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Glaucoma Market

• 14.1. South Korea Glaucoma Market Overview
• 14.2. South Korea Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Glaucoma Market

• 15.1. Western Europe Glaucoma Market Overview
• 15.2. Western Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Glaucoma Market

• 16.1. UK Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Glaucoma Market

• 17.1. Germany Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Glaucoma Market

• 18.1. France Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Glaucoma Market

• 19.1. Italy Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Glaucoma Market

• 20.1. Spain Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Glaucoma Market

• 21.1. Eastern Europe Glaucoma Market Overview
• 21.2. Eastern Europe Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Glaucoma Market

• 22.1. Russia Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Glaucoma Market

• 23.1. North America Glaucoma Market Overview
• 23.2. North America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Glaucoma Market

• 24.1. USA Glaucoma Market Overview
• 24.2. USA Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Glaucoma Market

• 25.1. Canada Glaucoma Market Overview
• 25.2. Canada Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Glaucoma Market

• 26.1. South America Glaucoma Market Overview
• 26.2. South America Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Glaucoma Market

• 27.1. Brazil Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Glaucoma Market

• 28.1. Middle East Glaucoma Market Overview
• 28.2. Middle East Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Glaucoma Market

• 29.1. Africa Glaucoma Market Overview
• 29.2. Africa Glaucoma Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Glaucoma Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Glaucoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Glaucoma Market Competitive Landscape And Company Profiles

• 30.1. Glaucoma Market Competitive Landscape
• 30.2. Glaucoma Market Company Profiles
  • 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Teva Pharmaceuticals Industries Ltd. Overview, Products and Services, Strategy and Financial Analysis

31. Glaucoma Market Other Major And Innovative Companies

• 31.1. Otsuka Pharmaceutical Co. Ltd.
• 31.2. Sun Pharmaceutical Industries Ltd.
• 31.3. Cipla Limited
• 31.4. Bausch & Lomb Corp.
• 31.5. Carl Zeiss Meditec
• 31.6. Santen Pharmaceuticals Co. Ltd.
• 31.7. Topcon Corporation
• 31.8. Thea Laboratoires
• 31.9. Corza Ophthalmology
• 31.10. Lumenis Ltd.
• 31.11. Alcon Inc.
• 31.12. Viva BioInnovator
• 31.13. Glaukos Corporation
• 31.14. Iridex Corporation
• 31.15. Nova Eye Medical Ltd.

32. Global Glaucoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Glaucoma Market

34. Recent Developments In The Glaucoma Market

35. Glaucoma Market High Potential Countries, Segments and Strategies

• 35.1 Glaucoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Glaucoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Glaucoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer